APO Research

APO RESEARCH · REPORT

Metformin Hydrochloride Sustained-release Drug

Selected research

Market Outlook & Growth Opportunities

Global Metformin Hydrochloride Sustained-release Drug Market Outlook and Growth Opportunities 2026

Market perspective

The global Metformin Hydrochloride Sustained-release Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Metformin Hydrochloride Sustained-release Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Metformin Hydrochloride Sustained-release Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Metformin Hydrochloride Sustained-release Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Metformin Hydrochloride Sustained-release Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Metformin Hydrochloride Sustained-release Drug market include Apotex, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, Viatris, Jingfeng Pharmaceutical Group, Beijing Shengyong Pharmaceutical, SinocorpPharma, Tianan Pharmaceutical and Jiangsu Deyuan Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Metformin Hydrochloride Sustained-release Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Metformin Hydrochloride Sustained-release Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Metformin Hydrochloride Sustained-release Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Metformin Hydrochloride Sustained-release Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Metformin Hydrochloride Sustained-release Drug Segment by Company

Apotex

Dr. Reddy's Laboratories

Sun Pharmaceutical Industries

Viatris

Jingfeng Pharmaceutical Group

Beijing Shengyong Pharmaceutical

SinocorpPharma

Tianan Pharmaceutical

Jiangsu Deyuan Pharmaceutical

Merck

Qingdao Huanghai Pharmaceutical

Shanghai Pharmaceuticals

CSPC

Teva Pharmaceuticals

Topfond Pharmaceutical

CTTQ

Chongqing Conquer Pharmaceutical

Metformin Hydrochloride Sustained-release Drug Segment by Type

Tablet

Capsule

Metformin Hydrochloride Sustained-release Drug Segment by Application

Hospital

Clinic

Other

Metformin Hydrochloride Sustained-release Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Metformin Hydrochloride Sustained-release Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Metformin Hydrochloride Sustained-release Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Metformin Hydrochloride Sustained-release Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Metformin Hydrochloride Sustained-release Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metformin Hydrochloride Sustained-release Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Metformin Hydrochloride Sustained-release Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metformin Hydrochloride Sustained-release Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Metformin Hydrochloride Sustained-release Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Metformin Hydrochloride Sustained-release Drug industry.

Chapter 3: Detailed analysis of Metformin Hydrochloride Sustained-release Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Metformin Hydrochloride Sustained-release Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Metformin Hydrochloride Sustained-release Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Metformin Hydrochloride Sustained-release Drug Industry Trends Table 2. Metformin Hydrochloride Sustained-release Drug Industry Drivers Table 3. Metformin Hydrochloride Sustained-release Drug Industry Opportunities and Challenges Table 4. Metformin Hydrochloride Sustained-release Drug Industry Restraints Table 5. Global Metformin Hydrochloride Sustained-release Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Metformin Hydrochloride Sustained-release Drug Revenue Share by Company (2021-2026) Table 7. Global Metformin Hydrochloride Sustained-release Drug Sales Volume by Company (k units) & (2021-2026) Table 8. Global Metformin Hydrochloride Sustained-release Drug Sales Volume Share by Company (2021-2026) Table 9. Global Metformin Hydrochloride Sustained-release Drug Average Price (US$/unit) of Company (2021-2026) Table 10. Global Metformin Hydrochloride Sustained-release Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Metformin Hydrochloride Sustained-release Drug Key Company Manufacturing Base & Headquarters Table 12. Global Metformin Hydrochloride Sustained-release Drug Company, Product Type & Application Table 13. Global Metformin Hydrochloride Sustained-release Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Metformin Hydrochloride Sustained-release Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Tablet Table 18. Significant Companies of Capsule Table 19. Global Metformin Hydrochloride Sustained-release Drug Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Metformin Hydrochloride Sustained-release Drug Sales Volume by Type (2021-2026) & (k units) Table 21. Global Metformin Hydrochloride Sustained-release Drug Sales Volume by Type (2027-2032) & (k units) Table 22. Global Metformin Hydrochloride Sustained-release Drug Sales Volume Share by Type (2021-2026) Table 23. Global Metformin Hydrochloride Sustained-release Drug Sales Volume Share by Type (2027-2032) Table 24. Global Metformin Hydrochloride Sustained-release Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Metformin Hydrochloride Sustained-release Drug Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Metformin Hydrochloride Sustained-release Drug Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type (2021-2026) Table 28. Global Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Significant Companies of Other Table 32. Global Metformin Hydrochloride Sustained-release Drug Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Metformin Hydrochloride Sustained-release Drug Sales Volume by Application (2021-2026) & (k units) Table 34. Global Metformin Hydrochloride Sustained-release Drug Sales Volume by Application (2027-2032) & (k units) Table 35. Global Metformin Hydrochloride Sustained-release Drug Sales Volume Share by Application (2021-2026) Table 36. Global Metformin Hydrochloride Sustained-release Drug Sales Volume Share by Application (2027-2032) Table 37. Global Metformin Hydrochloride Sustained-release Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Metformin Hydrochloride Sustained-release Drug Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Metformin Hydrochloride Sustained-release Drug Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application (2021-2026) Table 41. Global Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application (2027-2032) Table 42. Global Metformin Hydrochloride Sustained-release Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Metformin Hydrochloride Sustained-release Drug Sales by Region (2021-2026) & (k units) Table 44. Global Metformin Hydrochloride Sustained-release Drug Sales Market Share by Region (2021-2026) Table 45. Global Metformin Hydrochloride Sustained-release Drug Sales by Region (2027-2032) & (k units) Table 46. Global Metformin Hydrochloride Sustained-release Drug Sales Market Share by Region (2027-2032) Table 47. Global Metformin Hydrochloride Sustained-release Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Metformin Hydrochloride Sustained-release Drug Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Metformin Hydrochloride Sustained-release Drug Sales Value Share by Region (2021-2026) Table 50. Global Metformin Hydrochloride Sustained-release Drug Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Metformin Hydrochloride Sustained-release Drug Sales Value Share by Region (2027-2032) Table 52. Global Metformin Hydrochloride Sustained-release Drug Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Metformin Hydrochloride Sustained-release Drug Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Metformin Hydrochloride Sustained-release Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Metformin Hydrochloride Sustained-release Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Metformin Hydrochloride Sustained-release Drug Sales by Country (2021-2026) & (k units) Table 57. Global Metformin Hydrochloride Sustained-release Drug Sales Market Share by Country (2021-2026) Table 58. Global Metformin Hydrochloride Sustained-release Drug Sales by Country (2027-2032) & (k units) Table 59. Global Metformin Hydrochloride Sustained-release Drug Sales Market Share by Country (2027-2032) Table 60. Global Metformin Hydrochloride Sustained-release Drug Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Metformin Hydrochloride Sustained-release Drug Sales Value Market Share by Country (2021-2026) Table 62. Global Metformin Hydrochloride Sustained-release Drug Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Metformin Hydrochloride Sustained-release Drug Sales Value Market Share by Country (2027-2032) Table 64. Apotex Company Information Table 65. Apotex Business Overview Table 66. Apotex Metformin Hydrochloride Sustained-release Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Apotex Metformin Hydrochloride Sustained-release Drug Product Portfolio Table 68. Apotex Recent Development Table 69. Dr. Reddy's Laboratories Company Information Table 70. Dr. Reddy's Laboratories Business Overview Table 71. Dr. Reddy's Laboratories Metformin Hydrochloride Sustained-release Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Dr. Reddy's Laboratories Metformin Hydrochloride Sustained-release Drug Product Portfolio Table 73. Dr. Reddy's Laboratories Recent Development Table 74. Sun Pharmaceutical Industries Company Information Table 75. Sun Pharmaceutical Industries Business Overview Table 76. Sun Pharmaceutical Industries Metformin Hydrochloride Sustained-release Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Sun Pharmaceutical Industries Metformin Hydrochloride Sustained-release Drug Product Portfolio Table 78. Sun Pharmaceutical Industries Recent Development Table 79. Viatris Company Information Table 80. Viatris Business Overview Table 81. Viatris Metformin Hydrochloride Sustained-release Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Viatris Metformin Hydrochloride Sustained-release Drug Product Portfolio Table 83. Viatris Recent Development Table 84. Jingfeng Pharmaceutical Group Company Information Table 85. Jingfeng Pharmaceutical Group Business Overview Table 86. Jingfeng Pharmaceutical Group Metformin Hydrochloride Sustained-release Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Jingfeng Pharmaceutical Group Metformin Hydrochloride Sustained-release Drug Product Portfolio Table 88. Jingfeng Pharmaceutical Group Recent Development Table 89. Beijing Shengyong Pharmaceutical Company Information Table 90. Beijing Shengyong Pharmaceutical Business Overview Table 91. Beijing Shengyong Pharmaceutical Metformin Hydrochloride Sustained-release Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Beijing Shengyong Pharmaceutical Metformin Hydrochloride Sustained-release Drug Product Portfolio Table 93. Beijing Shengyong Pharmaceutical Recent Development Table 94. SinocorpPharma Company Information Table 95. SinocorpPharma Business Overview Table 96. SinocorpPharma Metformin Hydrochloride Sustained-release Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. SinocorpPharma Metformin Hydrochloride Sustained-release Drug Product Portfolio Table 98. SinocorpPharma Recent Development Table 99. Tianan Pharmaceutical Company Information Table 100. Tianan Pharmaceutical Business Overview Table 101. Tianan Pharmaceutical Metformin Hydrochloride Sustained-release Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Tianan Pharmaceutical Metformin Hydrochloride Sustained-release Drug Product Portfolio Table 103. Tianan Pharmaceutical Recent Development Table 104. Jiangsu Deyuan Pharmaceutical Company Information Table 105. Jiangsu Deyuan Pharmaceutical Business Overview Table 106. Jiangsu Deyuan Pharmaceutical Metformin Hydrochloride Sustained-release Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Jiangsu Deyuan Pharmaceutical Metformin Hydrochloride Sustained-release Drug Product Portfolio Table 108. Jiangsu Deyuan Pharmaceutical Recent Development Table 109. Merck Company Information Table 110. Merck Business Overview Table 111. Merck Metformin Hydrochloride Sustained-release Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Merck Metformin Hydrochloride Sustained-release Drug Product Portfolio Table 113. Merck Recent Development Table 114. Qingdao Huanghai Pharmaceutical Company Information Table 115. Qingdao Huanghai Pharmaceutical Business Overview Table 116. Qingdao Huanghai Pharmaceutical Metformin Hydrochloride Sustained-release Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Qingdao Huanghai Pharmaceutical Metformin Hydrochloride Sustained-release Drug Product Portfolio Table 118. Qingdao Huanghai Pharmaceutical Recent Development Table 119. Shanghai Pharmaceuticals Company Information Table 120. Shanghai Pharmaceuticals Business Overview Table 121. Shanghai Pharmaceuticals Metformin Hydrochloride Sustained-release Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Shanghai Pharmaceuticals Metformin Hydrochloride Sustained-release Drug Product Portfolio Table 123. Shanghai Pharmaceuticals Recent Development Table 124. CSPC Company Information Table 125. CSPC Business Overview Table 126. CSPC Metformin Hydrochloride Sustained-release Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. CSPC Metformin Hydrochloride Sustained-release Drug Product Portfolio Table 128. CSPC Recent Development Table 129. Teva Pharmaceuticals Company Information Table 130. Teva Pharmaceuticals Business Overview Table 131. Teva Pharmaceuticals Metformin Hydrochloride Sustained-release Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. Teva Pharmaceuticals Metformin Hydrochloride Sustained-release Drug Product Portfolio Table 133. Teva Pharmaceuticals Recent Development Table 134. Topfond Pharmaceutical Company Information Table 135. Topfond Pharmaceutical Business Overview Table 136. Topfond Pharmaceutical Metformin Hydrochloride Sustained-release Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Topfond Pharmaceutical Metformin Hydrochloride Sustained-release Drug Product Portfolio Table 138. Topfond Pharmaceutical Recent Development Table 139. CTTQ Company Information Table 140. CTTQ Business Overview Table 141. CTTQ Metformin Hydrochloride Sustained-release Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 142. CTTQ Metformin Hydrochloride Sustained-release Drug Product Portfolio Table 143. CTTQ Recent Development Table 144. Chongqing Conquer Pharmaceutical Company Information Table 145. Chongqing Conquer Pharmaceutical Business Overview Table 146. Chongqing Conquer Pharmaceutical Metformin Hydrochloride Sustained-release Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 147. Chongqing Conquer Pharmaceutical Metformin Hydrochloride Sustained-release Drug Product Portfolio Table 148. Chongqing Conquer Pharmaceutical Recent Development Table 149. Key Raw Materials Table 150. Raw Materials Key Suppliers Table 151. Metformin Hydrochloride Sustained-release Drug Distributors List Table 152. Metformin Hydrochloride Sustained-release Drug Customers List Table 153. Research Programs/Design for This Report Table 154. Authors List of This Report Table 155. Secondary Sources Table 156. Primary Sources List of Figures Figure 1. Metformin Hydrochloride Sustained-release Drug Product Image Figure 2. Global Metformin Hydrochloride Sustained-release Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Metformin Hydrochloride Sustained-release Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Metformin Hydrochloride Sustained-release Drug Sales (2021-2032) & (k units) Figure 5. Global Metformin Hydrochloride Sustained-release Drug Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Metformin Hydrochloride Sustained-release Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Tablet Image Figure 10. Capsule Image Figure 11. Global Metformin Hydrochloride Sustained-release Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Metformin Hydrochloride Sustained-release Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Metformin Hydrochloride Sustained-release Drug Sales Volume Share by Type (2021-2032) Figure 14. Global Metformin Hydrochloride Sustained-release Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Metformin Hydrochloride Sustained-release Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Other Image Figure 20. Global Metformin Hydrochloride Sustained-release Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Metformin Hydrochloride Sustained-release Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Metformin Hydrochloride Sustained-release Drug Sales Volume Share by Application (2021-2032) Figure 23. Global Metformin Hydrochloride Sustained-release Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Metformin Hydrochloride Sustained-release Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application (2021-2032) Figure 26. Global Metformin Hydrochloride Sustained-release Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Metformin Hydrochloride Sustained-release Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Metformin Hydrochloride Sustained-release Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Metformin Hydrochloride Sustained-release Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Metformin Hydrochloride Sustained-release Drug Sales Value (2021-2032) & (US$ Million) Figure 31. North America Metformin Hydrochloride Sustained-release Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Metformin Hydrochloride Sustained-release Drug Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Metformin Hydrochloride Sustained-release Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Metformin Hydrochloride Sustained-release Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Metformin Hydrochloride Sustained-release Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Metformin Hydrochloride Sustained-release Drug Sales Value (2021-2032) & (US$ Million) Figure 37. South America Metformin Hydrochloride Sustained-release Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Metformin Hydrochloride Sustained-release Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Metformin Hydrochloride Sustained-release Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Metformin Hydrochloride Sustained-release Drug Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Metformin Hydrochloride Sustained-release Drug Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Tablet
  • Capsule
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Apotex
  • Dr. Reddy's Laboratories
  • Sun Pharmaceutical Industries
  • Viatris
  • Jingfeng Pharmaceutical Group
  • Beijing Shengyong Pharmaceutical
  • SinocorpPharma
  • Tianan Pharmaceutical
  • Jiangsu Deyuan Pharmaceutical
  • Merck
  • Qingdao Huanghai Pharmaceutical
  • Shanghai Pharmaceuticals
  • CSPC
  • Teva Pharmaceuticals
  • Topfond Pharmaceutical
  • CTTQ
  • Chongqing Conquer Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Metformin Hydrochloride Sustained-release Drug Sales Value (2021-2032)
  4. 1.2.2 Global Metformin Hydrochloride Sustained-release Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Metformin Hydrochloride Sustained-release Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Metformin Hydrochloride Sustained-release Drug Market Dynamics
  1. 2.1 Metformin Hydrochloride Sustained-release Drug Industry Trends
  2. 2.2 Metformin Hydrochloride Sustained-release Drug Industry Drivers
  3. 2.3 Metformin Hydrochloride Sustained-release Drug Industry Opportunities and Challenges
  4. 2.4 Metformin Hydrochloride Sustained-release Drug Industry Restraints
3 Metformin Hydrochloride Sustained-release Drug Market by Company
  1. 3.1 Global Metformin Hydrochloride Sustained-release Drug Company Revenue Ranking in 2025
  2. 3.2 Global Metformin Hydrochloride Sustained-release Drug Revenue by Company (2021-2026)
  3. 3.3 Global Metformin Hydrochloride Sustained-release Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Metformin Hydrochloride Sustained-release Drug Average Price by Company (2021-2026)
  5. 3.5 Global Metformin Hydrochloride Sustained-release Drug Company Ranking (2024-2026)
  6. 3.6 Global Metformin Hydrochloride Sustained-release Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Metformin Hydrochloride Sustained-release Drug Company Product Type and Application
  8. 3.8 Global Metformin Hydrochloride Sustained-release Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Metformin Hydrochloride Sustained-release Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Metformin Hydrochloride Sustained-release Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Metformin Hydrochloride Sustained-release Drug Market by Type
  1. 4.1 Metformin Hydrochloride Sustained-release Drug Type Introduction
  2. 4.1.1 Tablet
  3. 4.1.2 Capsule
  4. 4.2 Global Metformin Hydrochloride Sustained-release Drug Sales Volume by Type
  5. 4.2.1 Global Metformin Hydrochloride Sustained-release Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Metformin Hydrochloride Sustained-release Drug Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Metformin Hydrochloride Sustained-release Drug Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Metformin Hydrochloride Sustained-release Drug Sales Value by Type
  9. 4.3.1 Global Metformin Hydrochloride Sustained-release Drug Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Metformin Hydrochloride Sustained-release Drug Sales Value by Type (2021-2032)
  11. 4.3.3 Global Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type (2021-2032)
5 Metformin Hydrochloride Sustained-release Drug Market by Application
  1. 5.1 Metformin Hydrochloride Sustained-release Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Metformin Hydrochloride Sustained-release Drug Sales Volume by Application
  6. 5.2.1 Global Metformin Hydrochloride Sustained-release Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Metformin Hydrochloride Sustained-release Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Metformin Hydrochloride Sustained-release Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Metformin Hydrochloride Sustained-release Drug Sales Value by Application
  10. 5.3.1 Global Metformin Hydrochloride Sustained-release Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Metformin Hydrochloride Sustained-release Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application (2021-2032)
6 Metformin Hydrochloride Sustained-release Drug Regional Sales and Value Analysis
  1. 6.1 Global Metformin Hydrochloride Sustained-release Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Metformin Hydrochloride Sustained-release Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Metformin Hydrochloride Sustained-release Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Metformin Hydrochloride Sustained-release Drug Sales by Region (2027-2032)
  5. 6.3 Global Metformin Hydrochloride Sustained-release Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Metformin Hydrochloride Sustained-release Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Metformin Hydrochloride Sustained-release Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Metformin Hydrochloride Sustained-release Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Metformin Hydrochloride Sustained-release Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Metformin Hydrochloride Sustained-release Drug Sales Value (2021-2032)
  12. 6.6.2 North America Metformin Hydrochloride Sustained-release Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Metformin Hydrochloride Sustained-release Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Metformin Hydrochloride Sustained-release Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Metformin Hydrochloride Sustained-release Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Metformin Hydrochloride Sustained-release Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Metformin Hydrochloride Sustained-release Drug Sales Value (2021-2032)
  21. 6.9.2 South America Metformin Hydrochloride Sustained-release Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Metformin Hydrochloride Sustained-release Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Metformin Hydrochloride Sustained-release Drug Sales Value Share by Country, 2025 VS 2032
7 Metformin Hydrochloride Sustained-release Drug Country-level Sales and Value Analysis
  1. 7.1 Global Metformin Hydrochloride Sustained-release Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Metformin Hydrochloride Sustained-release Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Metformin Hydrochloride Sustained-release Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Metformin Hydrochloride Sustained-release Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Metformin Hydrochloride Sustained-release Drug Sales by Country (2027-2032)
  6. 7.4 Global Metformin Hydrochloride Sustained-release Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Metformin Hydrochloride Sustained-release Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Metformin Hydrochloride Sustained-release Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Metformin Hydrochloride Sustained-release Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Metformin Hydrochloride Sustained-release Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Metformin Hydrochloride Sustained-release Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Apotex
  2. 8.1.1 Apotex Company Information
  3. 8.1.2 Apotex Business Overview
  4. 8.1.3 Apotex Metformin Hydrochloride Sustained-release Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Apotex Metformin Hydrochloride Sustained-release Drug Product Portfolio
  6. 8.1.5 Apotex Recent Developments
  7. 8.2 Dr. Reddy's Laboratories
  8. 8.2.1 Dr. Reddy's Laboratories Company Information
  9. 8.2.2 Dr. Reddy's Laboratories Business Overview
  10. 8.2.3 Dr. Reddy's Laboratories Metformin Hydrochloride Sustained-release Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Dr. Reddy's Laboratories Metformin Hydrochloride Sustained-release Drug Product Portfolio
  12. 8.2.5 Dr. Reddy's Laboratories Recent Developments
  13. 8.3 Sun Pharmaceutical Industries
  14. 8.3.1 Sun Pharmaceutical Industries Company Information
  15. 8.3.2 Sun Pharmaceutical Industries Business Overview
  16. 8.3.3 Sun Pharmaceutical Industries Metformin Hydrochloride Sustained-release Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sun Pharmaceutical Industries Metformin Hydrochloride Sustained-release Drug Product Portfolio
  18. 8.3.5 Sun Pharmaceutical Industries Recent Developments
  19. 8.4 Viatris
  20. 8.4.1 Viatris Company Information
  21. 8.4.2 Viatris Business Overview
  22. 8.4.3 Viatris Metformin Hydrochloride Sustained-release Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Viatris Metformin Hydrochloride Sustained-release Drug Product Portfolio
  24. 8.4.5 Viatris Recent Developments
  25. 8.5 Jingfeng Pharmaceutical Group
  26. 8.5.1 Jingfeng Pharmaceutical Group Company Information
  27. 8.5.2 Jingfeng Pharmaceutical Group Business Overview
  28. 8.5.3 Jingfeng Pharmaceutical Group Metformin Hydrochloride Sustained-release Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Jingfeng Pharmaceutical Group Metformin Hydrochloride Sustained-release Drug Product Portfolio
  30. 8.5.5 Jingfeng Pharmaceutical Group Recent Developments
  31. 8.6 Beijing Shengyong Pharmaceutical
  32. 8.6.1 Beijing Shengyong Pharmaceutical Company Information
  33. 8.6.2 Beijing Shengyong Pharmaceutical Business Overview
  34. 8.6.3 Beijing Shengyong Pharmaceutical Metformin Hydrochloride Sustained-release Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Beijing Shengyong Pharmaceutical Metformin Hydrochloride Sustained-release Drug Product Portfolio
  36. 8.6.5 Beijing Shengyong Pharmaceutical Recent Developments
  37. 8.7 SinocorpPharma
  38. 8.7.1 SinocorpPharma Company Information
  39. 8.7.2 SinocorpPharma Business Overview
  40. 8.7.3 SinocorpPharma Metformin Hydrochloride Sustained-release Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 SinocorpPharma Metformin Hydrochloride Sustained-release Drug Product Portfolio
  42. 8.7.5 SinocorpPharma Recent Developments
  43. 8.8 Tianan Pharmaceutical
  44. 8.8.1 Tianan Pharmaceutical Company Information
  45. 8.8.2 Tianan Pharmaceutical Business Overview
  46. 8.8.3 Tianan Pharmaceutical Metformin Hydrochloride Sustained-release Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Tianan Pharmaceutical Metformin Hydrochloride Sustained-release Drug Product Portfolio
  48. 8.8.5 Tianan Pharmaceutical Recent Developments
  49. 8.9 Jiangsu Deyuan Pharmaceutical
  50. 8.9.1 Jiangsu Deyuan Pharmaceutical Company Information
  51. 8.9.2 Jiangsu Deyuan Pharmaceutical Business Overview
  52. 8.9.3 Jiangsu Deyuan Pharmaceutical Metformin Hydrochloride Sustained-release Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Jiangsu Deyuan Pharmaceutical Metformin Hydrochloride Sustained-release Drug Product Portfolio
  54. 8.9.5 Jiangsu Deyuan Pharmaceutical Recent Developments
  55. 8.10 Merck
  56. 8.10.1 Merck Company Information
  57. 8.10.2 Merck Business Overview
  58. 8.10.3 Merck Metformin Hydrochloride Sustained-release Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Merck Metformin Hydrochloride Sustained-release Drug Product Portfolio
  60. 8.10.5 Merck Recent Developments
  61. 8.11 Qingdao Huanghai Pharmaceutical
  62. 8.11.1 Qingdao Huanghai Pharmaceutical Company Information
  63. 8.11.2 Qingdao Huanghai Pharmaceutical Business Overview
  64. 8.11.3 Qingdao Huanghai Pharmaceutical Metformin Hydrochloride Sustained-release Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Qingdao Huanghai Pharmaceutical Metformin Hydrochloride Sustained-release Drug Product Portfolio
  66. 8.11.5 Qingdao Huanghai Pharmaceutical Recent Developments
  67. 8.12 Shanghai Pharmaceuticals
  68. 8.12.1 Shanghai Pharmaceuticals Company Information
  69. 8.12.2 Shanghai Pharmaceuticals Business Overview
  70. 8.12.3 Shanghai Pharmaceuticals Metformin Hydrochloride Sustained-release Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Shanghai Pharmaceuticals Metformin Hydrochloride Sustained-release Drug Product Portfolio
  72. 8.12.5 Shanghai Pharmaceuticals Recent Developments
  73. 8.13 CSPC
  74. 8.13.1 CSPC Company Information
  75. 8.13.2 CSPC Business Overview
  76. 8.13.3 CSPC Metformin Hydrochloride Sustained-release Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 CSPC Metformin Hydrochloride Sustained-release Drug Product Portfolio
  78. 8.13.5 CSPC Recent Developments
  79. 8.14 Teva Pharmaceuticals
  80. 8.14.1 Teva Pharmaceuticals Company Information
  81. 8.14.2 Teva Pharmaceuticals Business Overview
  82. 8.14.3 Teva Pharmaceuticals Metformin Hydrochloride Sustained-release Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Teva Pharmaceuticals Metformin Hydrochloride Sustained-release Drug Product Portfolio
  84. 8.14.5 Teva Pharmaceuticals Recent Developments
  85. 8.15 Topfond Pharmaceutical
  86. 8.15.1 Topfond Pharmaceutical Company Information
  87. 8.15.2 Topfond Pharmaceutical Business Overview
  88. 8.15.3 Topfond Pharmaceutical Metformin Hydrochloride Sustained-release Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Topfond Pharmaceutical Metformin Hydrochloride Sustained-release Drug Product Portfolio
  90. 8.15.5 Topfond Pharmaceutical Recent Developments
  91. 8.16 CTTQ
  92. 8.16.1 CTTQ Company Information
  93. 8.16.2 CTTQ Business Overview
  94. 8.16.3 CTTQ Metformin Hydrochloride Sustained-release Drug Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 CTTQ Metformin Hydrochloride Sustained-release Drug Product Portfolio
  96. 8.16.5 CTTQ Recent Developments
  97. 8.17 Chongqing Conquer Pharmaceutical
  98. 8.17.1 Chongqing Conquer Pharmaceutical Company Information
  99. 8.17.2 Chongqing Conquer Pharmaceutical Business Overview
  100. 8.17.3 Chongqing Conquer Pharmaceutical Metformin Hydrochloride Sustained-release Drug Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Chongqing Conquer Pharmaceutical Metformin Hydrochloride Sustained-release Drug Product Portfolio
  102. 8.17.5 Chongqing Conquer Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Metformin Hydrochloride Sustained-release Drug Value Chain Analysis
  2. 9.1.1 Metformin Hydrochloride Sustained-release Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Metformin Hydrochloride Sustained-release Drug Sales Mode & Process
  6. 9.2 Metformin Hydrochloride Sustained-release Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Metformin Hydrochloride Sustained-release Drug Distributors
  9. 9.2.3 Metformin Hydrochloride Sustained-release Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research